| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 52 | 2022 | 544 | 9.920 |
Why?
|
| Pleural Neoplasms | 37 | 2022 | 470 | 7.140 |
Why?
|
| Lung Neoplasms | 85 | 2023 | 11538 | 4.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 52 | 2023 | 5319 | 3.210 |
Why?
|
| Quinazolines | 14 | 2022 | 923 | 1.850 |
Why?
|
| Pemetrexed | 7 | 2019 | 102 | 1.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2023 | 15862 | 1.390 |
Why?
|
| Cisplatin | 11 | 2020 | 2432 | 1.190 |
Why?
|
| Immunotherapy | 9 | 2023 | 3341 | 1.030 |
Why?
|
| Antineoplastic Agents | 23 | 2023 | 14289 | 1.010 |
Why?
|
| Biomarkers, Tumor | 20 | 2021 | 10331 | 0.980 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2014 | 153 | 0.930 |
Why?
|
| ErbB Receptors | 10 | 2023 | 2295 | 0.890 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2022 | 2104 | 0.870 |
Why?
|
| Clinical Trials as Topic | 12 | 2020 | 3719 | 0.830 |
Why?
|
| Pneumonectomy | 10 | 2021 | 831 | 0.810 |
Why?
|
| Gene Dosage | 4 | 2014 | 829 | 0.800 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2020 | 5437 | 0.770 |
Why?
|
| Pyrimidines | 9 | 2023 | 3518 | 0.710 |
Why?
|
| Precision Medicine | 6 | 2016 | 1154 | 0.710 |
Why?
|
| Dasatinib | 3 | 2020 | 862 | 0.680 |
Why?
|
| Humans | 133 | 2023 | 261506 | 0.680 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 261 | 0.630 |
Why?
|
| Exons | 7 | 2022 | 1328 | 0.580 |
Why?
|
| Indoles | 6 | 2023 | 1009 | 0.570 |
Why?
|
| Molecular Targeted Therapy | 6 | 2019 | 2330 | 0.560 |
Why?
|
| Carcinogenesis | 3 | 2019 | 1026 | 0.540 |
Why?
|
| Middle Aged | 65 | 2023 | 86204 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 5 | 2013 | 3976 | 0.540 |
Why?
|
| Aged | 61 | 2023 | 70117 | 0.540 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 1249 | 0.530 |
Why?
|
| Mutation | 17 | 2023 | 15179 | 0.500 |
Why?
|
| Male | 68 | 2023 | 123000 | 0.470 |
Why?
|
| Cytidine | 1 | 2013 | 24 | 0.460 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 406 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2020 | 10035 | 0.450 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 1547 | 0.440 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 1046 | 0.430 |
Why?
|
| Female | 70 | 2023 | 141928 | 0.430 |
Why?
|
| Ipilimumab | 6 | 2023 | 710 | 0.430 |
Why?
|
| Survival Rate | 17 | 2021 | 12221 | 0.420 |
Why?
|
| Piperazines | 5 | 2013 | 2101 | 0.420 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 8 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 4975 | 0.410 |
Why?
|
| Neoplasm Staging | 20 | 2023 | 13658 | 0.410 |
Why?
|
| Treatment Outcome | 28 | 2023 | 32848 | 0.400 |
Why?
|
| Disease-Free Survival | 17 | 2017 | 10001 | 0.390 |
Why?
|
| Piperidines | 2 | 2013 | 1035 | 0.380 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 323 | 0.370 |
Why?
|
| Societies, Medical | 1 | 2016 | 1335 | 0.370 |
Why?
|
| Hypopigmentation | 2 | 2004 | 28 | 0.360 |
Why?
|
| Tea | 1 | 2009 | 43 | 0.360 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 7789 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2023 | 4757 | 0.350 |
Why?
|
| Mitosis | 1 | 2011 | 615 | 0.340 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 29902 | 0.340 |
Why?
|
| Pleura | 3 | 2021 | 127 | 0.340 |
Why?
|
| Prognosis | 18 | 2022 | 21713 | 0.340 |
Why?
|
| Phytotherapy | 1 | 2009 | 110 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2013 | 2488 | 0.330 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2022 | 2231 | 0.330 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2020 | 211 | 0.320 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2009 | 156 | 0.310 |
Why?
|
| Medical Oncology | 1 | 2016 | 1423 | 0.310 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 388 | 0.310 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 235 | 0.310 |
Why?
|
| Plant Extracts | 1 | 2009 | 215 | 0.310 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2022 | 3890 | 0.300 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2007 | 96 | 0.300 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 661 | 0.290 |
Why?
|
| Adult | 41 | 2023 | 77950 | 0.290 |
Why?
|
| Thoracic Neoplasms | 3 | 2019 | 337 | 0.290 |
Why?
|
| Papillomaviridae | 1 | 2010 | 624 | 0.290 |
Why?
|
| Combined Modality Therapy | 11 | 2019 | 8865 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2403 | 0.270 |
Why?
|
| Imatinib Mesylate | 5 | 2013 | 1665 | 0.270 |
Why?
|
| Proton Therapy | 4 | 2020 | 1577 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 5159 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2004 | 479 | 0.260 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 1022 | 0.250 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2004 | 2527 | 0.250 |
Why?
|
| Benzamides | 5 | 2013 | 1832 | 0.250 |
Why?
|
| Mouth Neoplasms | 1 | 2009 | 713 | 0.240 |
Why?
|
| Asbestos | 3 | 2019 | 35 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 6207 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2020 | 3251 | 0.240 |
Why?
|
| Acrylamides | 1 | 2023 | 53 | 0.230 |
Why?
|
| Neoplasm Metastasis | 6 | 2019 | 5112 | 0.230 |
Why?
|
| Aniline Compounds | 2 | 2023 | 177 | 0.230 |
Why?
|
| Thiazoles | 1 | 2007 | 726 | 0.220 |
Why?
|
| Bronchial Neoplasms | 1 | 2003 | 79 | 0.220 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 1058 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2019 | 2054 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 1879 | 0.210 |
Why?
|
| Taxoids | 4 | 2017 | 967 | 0.210 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 362 | 0.210 |
Why?
|
| Genes, erbB | 1 | 2021 | 26 | 0.200 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 980 | 0.200 |
Why?
|
| Niacinamide | 2 | 2013 | 421 | 0.200 |
Why?
|
| Bevacizumab | 5 | 2019 | 938 | 0.200 |
Why?
|
| Cell Cycle | 1 | 2007 | 2084 | 0.200 |
Why?
|
| Melanoma | 3 | 2023 | 5317 | 0.200 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2018 | 160 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2014 | 731 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2022 | 2588 | 0.180 |
Why?
|
| Spouses | 2 | 2020 | 134 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.180 |
Why?
|
| Consensus | 3 | 2019 | 978 | 0.180 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 4988 | 0.180 |
Why?
|
| Radiation Dosage | 2 | 2022 | 1014 | 0.180 |
Why?
|
| Azepines | 1 | 2020 | 124 | 0.180 |
Why?
|
| Phenylurea Compounds | 2 | 2013 | 580 | 0.180 |
Why?
|
| Mindfulness | 1 | 2020 | 58 | 0.180 |
Why?
|
| Cell Movement | 1 | 2007 | 2466 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 6 | 2020 | 4367 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 138 | 0.170 |
Why?
|
| Smoking | 2 | 2019 | 2440 | 0.170 |
Why?
|
| United States | 11 | 2020 | 15433 | 0.170 |
Why?
|
| Neoplasms | 5 | 2022 | 15193 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.170 |
Why?
|
| Quality of Life | 8 | 2022 | 4532 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 155 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2019 | 90 | 0.160 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 24 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2019 | 128 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 1283 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2018 | 15 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2518 | 0.160 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2022 | 216 | 0.160 |
Why?
|
| Dyspnea | 2 | 2022 | 416 | 0.160 |
Why?
|
| Mind-Body Therapies | 1 | 2017 | 29 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2021 | 9244 | 0.150 |
Why?
|
| Radiation Injuries | 3 | 2014 | 1411 | 0.150 |
Why?
|
| ras Proteins | 3 | 2013 | 770 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2022 | 1823 | 0.150 |
Why?
|
| Survival Analysis | 6 | 2014 | 9180 | 0.150 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 74 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 2232 | 0.150 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 124 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 7551 | 0.140 |
Why?
|
| Retrospective Studies | 13 | 2022 | 37905 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 5539 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1048 | 0.140 |
Why?
|
| Dexamethasone | 2 | 2022 | 1450 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2017 | 163 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2021 | 1987 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 607 | 0.130 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 327 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 1290 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 550 | 0.130 |
Why?
|
| Leukemia | 1 | 2004 | 1635 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2022 | 5178 | 0.130 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 304 | 0.130 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 657 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 1331 | 0.130 |
Why?
|
| Lung | 4 | 2020 | 3151 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 246 | 0.120 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2014 | 29 | 0.120 |
Why?
|
| Radiation Pneumonitis | 1 | 2016 | 301 | 0.120 |
Why?
|
| Apoptosis | 2 | 2014 | 7591 | 0.120 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 1946 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 657 | 0.120 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2013 | 104 | 0.120 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 14889 | 0.120 |
Why?
|
| Glutamates | 1 | 2013 | 130 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.120 |
Why?
|
| Lipocalins | 1 | 2013 | 54 | 0.110 |
Why?
|
| Interleukin-9 | 1 | 2013 | 37 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.110 |
Why?
|
| Guanine | 1 | 2013 | 151 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 65 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 519 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 669 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 79 | 0.110 |
Why?
|
| Placebos | 2 | 2015 | 437 | 0.110 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 101 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 400 | 0.110 |
Why?
|
| Microtubules | 1 | 2014 | 270 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.110 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 205 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 332 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 442 | 0.110 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2012 | 116 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 80 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1824 | 0.100 |
Why?
|
| Postoperative Complications | 4 | 2021 | 5542 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 1162 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 134 | 0.100 |
Why?
|
| Patient Selection | 2 | 2017 | 2055 | 0.100 |
Why?
|
| Risk Factors | 5 | 2019 | 17523 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 1248 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 814 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2016 | 2292 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 1450 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 146 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3639 | 0.090 |
Why?
|
| Neoplasm Seeding | 1 | 2009 | 66 | 0.090 |
Why?
|
| Genomics | 4 | 2021 | 2738 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2011 | 1544 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4654 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 208 | 0.080 |
Why?
|
| Genes, ras | 1 | 2012 | 667 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 598 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2013 | 11965 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 4892 | 0.080 |
Why?
|
| Adolescent | 6 | 2023 | 31252 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 875 | 0.080 |
Why?
|
| Radiotherapy Dosage | 4 | 2020 | 3842 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2004 | 371 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3869 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2020 | 2803 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 1533 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2019 | 2218 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 289 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 669 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2014 | 6150 | 0.070 |
Why?
|
| Disease Progression | 4 | 2020 | 6682 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2011 | 902 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 14551 | 0.060 |
Why?
|
| CD13 Antigens | 1 | 2004 | 36 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 5687 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2014 | 8873 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 4938 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 1764 | 0.060 |
Why?
|
| Topotecan | 1 | 2004 | 239 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 3981 | 0.060 |
Why?
|
| Phenotype | 1 | 2014 | 6295 | 0.060 |
Why?
|
| Young Adult | 4 | 2018 | 21445 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 7548 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2004 | 241 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 593 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 206 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2020 | 12873 | 0.050 |
Why?
|
| Carbamates | 1 | 2021 | 77 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 4844 | 0.050 |
Why?
|
| Bronchi | 1 | 2003 | 326 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2004 | 4804 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 2967 | 0.050 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2001 | 10 | 0.050 |
Why?
|
| Carcinoma | 1 | 2013 | 2578 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 3154 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 2054 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1616 | 0.050 |
Why?
|
| Epithelium | 1 | 2003 | 720 | 0.050 |
Why?
|
| Carboplatin | 2 | 2016 | 823 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 1391 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 1 | 2021 | 218 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2003 | 474 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 205 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2170 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 20 | 0.040 |
Why?
|
| Polymers | 1 | 2001 | 223 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 41 | 0.040 |
Why?
|
| Foundations | 1 | 2019 | 26 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 107 | 0.040 |
Why?
|
| Australia | 1 | 2019 | 225 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 76 | 0.040 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 45 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 544 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 318 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 482 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1062 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 419 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 428 | 0.040 |
Why?
|
| Pneumonia | 2 | 2017 | 751 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1163 | 0.040 |
Why?
|
| Metacarpus | 1 | 1997 | 5 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Alveolar Bone Loss | 1 | 1997 | 7 | 0.040 |
Why?
|
| Legislation, Drug | 1 | 2018 | 17 | 0.040 |
Why?
|
| Alveolar Process | 1 | 1997 | 10 | 0.040 |
Why?
|
| Gingiva | 1 | 1997 | 18 | 0.040 |
Why?
|
| Palliative Care | 1 | 2009 | 2037 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 323 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1819 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 649 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4298 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2019 | 244 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 1363 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1997 | 105 | 0.040 |
Why?
|
| Menopause | 1 | 1997 | 159 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 690 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2017 | 112 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2017 | 219 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 717 | 0.040 |
Why?
|
| Research Design | 2 | 2017 | 1544 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2003 | 1678 | 0.040 |
Why?
|
| Saliva | 1 | 1997 | 231 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 1546 | 0.040 |
Why?
|
| Spirituality | 1 | 2017 | 129 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 799 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 3101 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Sleep Stages | 1 | 2016 | 78 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 452 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 714 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 143 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 834 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 148 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 992 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 461 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 441 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2359 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 5395 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4758 | 0.030 |
Why?
|
| Bone Density | 1 | 1997 | 476 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 509 | 0.030 |
Why?
|
| Age Factors | 1 | 2004 | 5377 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 677 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 750 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 277 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 348 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 65 | 0.030 |
Why?
|
| Epothilones | 1 | 2014 | 54 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1146 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 288 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1648 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1656 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 387 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 6869 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 226 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 1833 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 317 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 1038 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2021 | 1823 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 415 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6100 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 760 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 481 | 0.030 |
Why?
|
| Genome, Human | 1 | 2020 | 1869 | 0.030 |
Why?
|
| Biomarkers | 1 | 2003 | 5047 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2012 | 126 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2341 | 0.020 |
Why?
|
| Valine | 1 | 2012 | 176 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 169 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 392 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 268 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2014 | 739 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2017 | 1000 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 591 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2013 | 696 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 2370 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 886 | 0.020 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2009 | 26 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2594 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 598 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4744 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 289 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 80 | 0.020 |
Why?
|
| Esophagitis | 1 | 2011 | 202 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 6009 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 1259 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 665 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 3578 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3230 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 60 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2283 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2307 | 0.020 |
Why?
|
| Protons | 1 | 2011 | 473 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 997 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3536 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 2508 | 0.020 |
Why?
|
| Depression | 1 | 2017 | 1715 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1439 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 702 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 5767 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1756 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1694 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 1487 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3570 | 0.020 |
Why?
|
| Proteome | 1 | 2009 | 561 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1859 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2045 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 987 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 1442 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 2074 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 1996 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 553 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 4233 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2009 | 977 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3343 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 6089 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2003 | 255 | 0.010 |
Why?
|
| Colorimetry | 1 | 2001 | 31 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7226 | 0.010 |
Why?
|
| Microspheres | 1 | 2001 | 210 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 3254 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 585 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 15694 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2003 | 1350 | 0.010 |
Why?
|
| Animals | 1 | 2018 | 59536 | 0.010 |
Why?
|